Morning Market Losers

shares fell 7.57% to $16.61. GSK and Theravance announced the outcome of US FDA Advisory Committee on BREO(R) ELLIPTA(R) in asthma. Glaxo and Theravance announced that the FDA panel has voted to support efficacy and safety. The panel has voted against the approval for proposed indication in 12-17 olds.

shares dipped 6.86% to $87.09 following announcement of Simon final offer. Simon Property Group Inc

raised its offer for Macerich to $95.50 per share in cash and stock.

fell 3.65% to $10.27. Cerulean Pharma announced that a Phase 1b/2 trial of CRLX101 in combination with Avastin® in relapsed renal cell carcinoma met primary endpoint.

shares dropped 1.26% to $85.28, despite the company reporting in-line earnings for the fourth quarter. The company's weak forecast exerted pressure on the shares.

shares declined 1.21% to $1.63 after the company announced at-the-market $10 million dollar offering at $1.7125 per share.

slipped 1.20% to $8.20 after the company reported a wider-than-expected quarterly loss.